31 results about "Bone morphogenetic protein 7" patented technology

Bone morphogenetic proteins (BMPs) are introduced into an affected intervertebral disc without the inclusion of disc cells. The inventions applies to all known and yet-to-be developed or discovered BMPs, including BMP-1, -2, -3, -4, -5, -6, -7, -8, -9, -10, . . . BMPn. The BMP(s) may be obtained from natural and/or recombinant sources. The BMP(s) may be introduced using any surgical technique, including percutaneous or laparoscopic approaches. As one delivery mechanism, a passageway may be formed through the annulus, with the substances then being introduced through the passageway. Alternatively, a carrier may be sewn or otherwise adhered to the inside or outside of the existing annulus using standard surgical procedures. Additional therapeutic substances such as culture medium, growth factors, differentiation factors, hydrogels, polymers, antibiotics, anti-inflammatory medications, or immunosuppressive medications could be introduced in conjunction with the BMP(s).

The invention relates to a 3D print scaffold material and a preparation method and application thereof and particularly relates to a 3D print scaffold material for periodontal tissue reconstruction and a preparation method and thereof. The material comprises the following components: a stromal cell-derived factor-1 (stromal cell-derived factor-1, SDF-1) and a bone morphogenetic protein 2 (Bone Morphogenetic Proteins, BMPs). By adopting two functional molecules of SDF-1 and BMP2, endogenous stem cells are collected into a periodontal defect area, osteogenic differentiation is accelerated, periodontal tissue regeneration is accelerated, meanwhile, an individual bionic degradable polymer scaffold is designed on the basis of 3D printing, and the external form and the internal microstructure of the material is precisely controlled through a computer.

The invention belongs to the field of a biomedical material, which is mainly applied to the preparation of a compound dosage form both of bone morphogenetic protein 2 active peptide and hydroxyapatite, wherein a sequence of the bone morphogenetic protein 2 active peptide is represented by SEQ ID NO: 1-10. A preparation method provided by the invention comprises the following steps: dissolving the bone morphogenetic protein 2 active peptide into normal saline or 5% of glucose solution, and then adding a hydroxyapatite support, combining the bone morphogenetic protein 2 active peptide on the surfaces of the hydroxyapatite particles to obtain the necessary compound dosage form both of the bone morphogenetic protein and hydroxyapatite after centrifugal separation, washing and drying, so as to obtain a human hard tissue repair material provided by the invention.

The present disclosure provides compositions and methods for reducing or inhibiting vascular inflammation, for example inflammation resulting from unstable blood flow conditions such as oscillatory shear. Representative compositions include an antagonist of BMPs, for example BMP4, or BMP receptors, for example BMPR-I and/or BMPR-II, in an amount sufficient to for inhibiting or reducing vascular inflammation by interfering with binding of bone morphogenic protein or a fragment thereof to bone morphogenic protein receptors. Exemplary BMP antagonists include polypeptides having an eight-, nine-, or ten-membered ring cystine knot structure. Representative BMP antagonists include, but are not limited to the CAN family of proteins, the chordin family that includes chordin and ventroptin, and noggin.

A mesenchymal stem cell extract and its use are provided, wherein the mesenchymal stem cell extract comprises a trophic factor(s), such as bone morphogenetic protein-7 (BMP-7), stromal cell-derived factor-1 (SDF-1), vascular endothelial growth factor (VEGF), C-X-C chemokine receptor type-4 (CXCR4), brain-derived neurotrophic factor (BDNF), and/or interleukin-17 (IL-17), and wherein the extract is especially suitable for repairing skin aging.

The invention discloses an application of bone morphogenetic protein-4 in screening drugs for resisting cardiac hypertrophy, heart failure or cardiac fibrosis and belongs to the field of biomedicine. Screened drug types comprise: bone morphogenetic protein-4 formation inhibitor, bone morphogenetic protein-4 antagonistic, bone morphogenetic protein-4 receptor antagonists and bone morphogenetic protein-4 downstream signal antagonistic. The invention also relates to an application of the drugs in preparation of medicines for resisting cardiac hypertrophy, heart failure and arrhythmia. Researches have found that bone morphogenetic protein-4 can induce myocardial hypertrophy, apoptosis and cardiac fibroblast collagen secretion increase, lead to occurrence of cardiac hypertrophy, heart failure and arrhythmia. However, drugs for antagonism of bone morphogenetic protein-4 and its cell signaling pathway can be used to inhibit occurrence of cardiac hypertrophy, inhibit cardiac fibrosis and minimize occurrence of cardiac cell death and arrhythmia. The invention provides a theoretical basis for realizing high-flux medicine screening, and is of practical guiding significance.

The present invention relates to a method of inducing neuronal production in a subject, a method of recruiting neurons to a subject's brain, and a method of treating a neurodegenerative condition by administering a neurotrophic factor and an inhibitor of pro-gliogenic bone morphogenetic proteins. Also disclosed is a method of suppressing astrocyte generation and inducing neuronal production in a subject, a method of treating a neurologic condition, and a method of suppressing glial scar formation in a subject by administering an inhibitor of pro-gliogenic bone morphogenetic proteins. Finally, the present invention involves a method of introducing a heterogeneous protein into a subject's brain and spinal cord by introducing a nucleic acid molecule encoding the heterogeneous protein introduced into the subject's ependyma, permitting the protein from the nucleic acid molecule to be expressed within the subject's ependyma, and permitting the expressed protein to migrate within the subject's brain and spinal cord.

Disclosed herein is an osteogenic synthetic peptide, derived from bone morphogenetic protein-7, consisting of a sequence of 15 amino acid residues. Provided are also a pharmaceutical composition and a medium composition comprising the same. Having remarkable activity related to promoting osteoblast differentiation, the osteogenic synthetic peptide is very useful in the treatment of osteoporosis, bone defects and/or osteoarthritis.

Compositions and methods useful for targeted depletion or modulation of dendritic cells are provided. The compositions and methods can be used to promote healing of ischemia-related injury, including ischemia-reperfusion injury. Disclosed are a variety of dendritic cell-targeted toxins, bone morphogenetic protein 7 (BMP7) agonists, and dendritic cell-targeted transforming growth factor beta 1 (TGF-β1) antagonists, all useful in practicing methods of the invention. The inventive compositions and methods can be used in the treatment of various conditions including myocardial infarction, stroke, and critical limb ischemia.

Disclosed are methods for identifying agents which modulate the activity of bone morphogenetic protein-7. These methods for identifying agents utilize bone morphogenetic protein receptors, specifically the daf-4 receptor, and more specifically the extracellular domain of the daf-4 receptor. Agents identified by the methods are also described as well as compositions comprising the agents and methods of treating a subject using the agents or compositions.

A drug for promoting bone morphogenetie protein expression to accelerate fracture healing is prepared by carboxymethylation of sodium alginate. The drug is prepared by the steps: adding 15 g of a sodium hydroxide liquid (2 mol/L) into each 100 g of sodium alginate, mixing uniformly, and stirring for 0.5 h at the temperature of 35 DEG C; then adding a mixture of 20 g of monochloroacetic acid and 20 g of sodium hydroxide according to each 100 g of sodium alginate, carrying out a stirring reaction for 3 h under a condition of the temperature of 70-80 DEG C, and thus obtaining a carboxymethyl sodium alginate resultant. The drug also can be prepared by in a 95% ethanol solution, taking sodium alginate, sodium hydroxide and monochloroacetic acid and carrying out a one-pot frying method, and particularly is prepared by the steps: according to the ratio of mass, mass and volume of 1:0.35:0.30, taking sodium alginate, sodium hydroxide and monochloroacetic acid, putting into the 95 vol% ethanol solution with the volume of 2 times that of the mixture, and carrying out a reaction under conditions of the etherification temperature of 50 DEG C and the etherification time of 3 h; and washing the reaction product with 95% ethanol, precipitating for 24 h, drying the resultant, and thus obtaining the carboxymethyl sodium alginate resultant. The obtained carboxymethyl sodium alginate is capable of promoting the bone morphogenetie protein expression, and is used in drugs for treating and preventing fractures, bone nonunion, osteonecrosis of the femoral head, and osteoporosis.

A method of improving renal function in a mammal suffering from, or at risk of developing, at least partial renal failure or renal dysfunction, includes administering to renal tissue of the mammal, a combination comprising a non-viral vector comprising a non-viral particulate carrier which carries a therapeutically effective amount of genetic material capable of expressing a renal function-enhancing Osteogenic Protein-1/Bone Morphogenic Protein-7 (OP-1/BMP-7) polypeptide in the renal tissue.

The invention discloses a dissoluble preparation of bone morphogenetic protein-7, which contains bone morphogenetic protein-7, L-arginine or/and urea, protein stabilizer and water for injection, and has the advantages that the solubility is high, and deposition does not occur in the serum, and the consistence can reach 0.2-1.0 mg/ml. The dissoluble preparation of bone morphogenetic protein-7 of the invention can be used for curing clinical kidney disease and vascular calcification, and for curing resumption of cerebral apoplexy, and liver and lung fibrosis as well.

The invention discloses a method of distinguishing a dorsal muscle and a tail muscle of Tilapia mossambica. The method is characterized in that a detected BMP (Bone Morphogenetic Protein) 4 antibody of Tilapia mossambica is used to detect the BMP4 proteins in the two muscle parts of Tilapia mossambica, and GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) is used as a contrast to a target protein, and if proteins of 55KD are just detected, the muscle is the dorsal muscle of Tilapia mossambica.

The invention relates to a method for maintaining the activity of bone morphogenetic protein-2 under an irradiation sterilization condition. The method comprises the following steps of adding a BMP-2 solution into a centrifugal pipe, sealing by a sealing membrane, putting into a thermal insulation bottle, filling with ice, irradiating by 60Co, 137Cs, 192Ir source rays, setting the dosage to be 0.01-100kGy, and carrying out the irradiation process of BMP-2. The method has the advantages that the inactivation problem in the BMP-2 irradiation process is solved effectively, the research development of medical treatment equipment for loading BMP-2 is pushed, and the application prospect is improved greatly.